Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.55 |
| ▸ | KIF11 | P52732 | 1/20 | 0.55 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 3/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30159619 | 1.00 | NPC1 (0.63) | NPC1NR4A2KIF11ASH1LRAB9A | |
| SCHEMBL14120820 | 0.87 | GPR84 (0.60) | NPC1NR4A2KIF11RAB9AGPR84 | |
| SCHEMBL29287217 | 0.86 | PDE4A (0.49) | NPC1NR4A2KIF11ASH1LRAB9A | |
| SCHEMBL12209328 | 0.84 | IMPDH2 (0.64) | NPC1RAB9APDE4APDE4BPDE4C | |
| SCHEMBL6418495 | 0.84 | NR4A2 (0.72) | NPC1NR4A2KIF11ASH1LRAB9A | |
| SCHEMBL21824109 | 0.83 | GABRA1 (0.49) | NPC1NR4A2KIF11ASH1LRAB9A | |
| SCHEMBL2804991 | 0.83 | NPC1 (0.62) | NPC1NR4A2KIF11ASH1LRAB9A | |
| SCHEMBL146334 | 0.83 | NPC1 (0.62) | NPC1NR4A2KIF11ASH1LRAB9A | |
| SCHEMBL3878724 | 0.83 | NPC1 (0.62) | NPC1NR4A2KIF11ASH1LRAB9A | |
| SCHEMBL19475912 | 0.83 | NPC1 (0.62) | NPC1NR4A2KIF11ASH1LRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236624-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-24 | — | — | US | disclosed |
| CN-115427035-B | ENL/AF9 YEATS inhibitors | 洛克菲勒大学 | 2025-04-22 | — | — | CN | disclosed |
| EP-4313972-B1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARM SPA (IT) | 2025-01-29 | — | — | EP | disclosed |
| US-20250002471-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2025-01-02 | — | — | US | disclosed |
| CN-115650985-B | Heterocyclic compounds as RET kinase inhibitors | 癌症研究科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-07-04 | — | — | US | disclosed |
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-07-04 | — | — | US | disclosed |
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-07-04 | — | — | US | disclosed |
| CN-115260180-B | Triazole condensed ring derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-4313972-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-02-07 | — | — | EP | disclosed |
| US-6410584-B1 | ANTICANCER AGENTS | CELL PATHWAYS, INC. | 2002-06-25 | — | — | US | disclosed |
| US-6358992-B1 | Method of inhibiting neoplastic cells with indole derivatives | CELL PATHWAYS, INC. | 2002-03-19 | — | — | US | disclosed |
| US-6303600-B1 | USED IN THERAPY OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY | RHONE-POULENC RORER LIMITED (GB) | 2001-10-16 | — | — | US | disclosed |
| US-6069156-A | Indole derivatives as cGMP-PDE inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-05-30 | — | — | US | disclosed |
| EP-0934307-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| CN-1187812-A | Indole derivatives as CGMP-PDE inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-07-15 | — | — | CN | disclosed |
| WO-1998005327-A1 | SUBSTITUTED AROMATIC COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| EP-0820441-A1 | INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-28 | — | — | EP | disclosed |
| WO-1997048697-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1997-12-24 | — | — | WO | disclosed |
| WO-1996032379-A1 | INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002471-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | SSB, IDO1, IDO2 | NPC1 2090/4885NR4A2 2418/4885KIF11 4656/4885 |
| US-20250236624-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, REL, BCR | NPC1 3915/4885NR4A2 284/4885KIF11 3969/4885 |
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | DDR1, DDR2, DDRGK1 | NPC1 3820/4885NR4A2 1190/4885KIF11 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.